Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TOP2A | P11388 | 7/20 | 0.71 |
| ▸ | MAOA | P21397 | 1/20 | 0.62 |
| ▸ | POLB | P06746 | 1/20 | 0.60 |
| ▸ | MGAM | O43451 | 1/20 | 0.59 |
| ▸ | GAA | P10253 | 1/20 | 0.59 |
| ▸ | SI | P14410 | 1/20 | 0.59 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11028362 | 0.90 | TOP2A (0.70) | TOP2AMAOAPOLBMGAMGAA | |
| SCHEMBL7337770 | 0.83 | MAOA (0.57) | TOP2AMAOA | |
| SCHEMBL11031411 | 0.82 | TOP2A (0.75) | TOP2AMAOAMGAM | |
| SCHEMBL11029659 | 0.81 | POLB (0.79) | TOP2AMAOAPOLBMGAMGAA | |
| SCHEMBL28380092 | 0.77 | MAOA (1.00) | MAOAPOLBMGAMGAASI | |
| SCHEMBL9314341 | 0.77 | TOP2A (0.69) | TOP2AMAOA | |
| SCHEMBL11030589 | 0.77 | MAOA (0.62) | TOP2AMAOAPOLBMGAMGAA | |
| SCHEMBL11026526 | 0.76 | MAOA (0.65) | TOP2AMAOA | |
| SCHEMBL30346407 | 0.75 | MGAM (1.00) | MAOAMGAMGAASIMGAM2 | |
| SCHEMBL2314333 | 0.75 | MGAM (1.00) | MAOAMGAMGAASIMGAM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120190724-A1 | NOVEL ANTICANCER-AIDING COMPOUND, METHOD FOR PREPARING THE SAME, ANTICANCER-AIDING COMPOSITION CONTAINING THE SAME AND METHOD FOR REDUCING ANTICANCER DRUG RESISTANCE USING THE SAME | EWHA UNIVERSITY INDUSTRY COLLABORATION FOUNDATION (KR) | 2012-07-26 | — | — | US | claimed |
| US-8846749-B2 | Anticancer-aiding compound, method for preparing the same, anticancer-aiding composition containing the same and method for reducing anticancer drug resistance using the same | EWHA UNIVERSITY-INDUSTRY COLLABORATION FOUNDATION (KR) | 2014-09-30 | — | — | US | disclosed |
| US-20120190724-A1 | NOVEL ANTICANCER-AIDING COMPOUND, METHOD FOR PREPARING THE SAME, ANTICANCER-AIDING COMPOSITION CONTAINING THE SAME AND METHOD FOR REDUCING ANTICANCER DRUG RESISTANCE USING THE SAME | EWHA UNIVERSITY INDUSTRY COLLABORATION FOUNDATION (KR) | 2012-07-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120190724-A1 | NOVEL ANTICANCER-AIDING COMPOUND, METHOD FOR PREPARING THE SAME, ANTICANCER-AIDING COMPOSITION CONTAINING THE SAME AND METHOD FOR REDUCING ANTICANCER DRUG RESISTANCE USING THE SAME | ABCC1, ANXA1, ANXA5 | TOP2A 49/4885MAOA 4052/4885POLB 1806/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.